Latest From Biotech Now

Life Science Leader Asks: What Areas Are Often Overlooked by Academics Turned Biotech Entrepreneurs?

Life Science Leader

In my third installment of a four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas & Associates, he shared missteps made by academics aspiring to become entrepreneurs and also offered up some advice on partnering with VCs. Check out my interview, which will include lessons that won’t be a part of his 2015 BIO International Convention session, Inventing Your Own Hub: Evolving Institutional Models for Translational Medicine, (June 16, 3:30 p.m.-4:45 p.m., room 105AB) Here is Part 1, Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

State of the Industry for Emerging Therapeutic Companies

Emerging Therapeutic Company Investment and Deal Trends

Emerging therapeutic companies are at their strongest point in a decade. In our new report on investment and deal trends, the BIO Industry Analysis team shows how this segment within the biotech industry has been faring over the last 10 years. The annual aggregate totals show that for almost every funding or deal activity analyzed, 2014 was the peak year of the last decade. A strong public market, a revitalized private funding environment, and a Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?

Williams-headshot

In 2009, Congress passed the Biologics Price Competition and Innovation Act (“BPCIA”), which for the first time provided for biosimilar or interchangeable biological drug products.  But it was not until March 6, 2015, that the FDA approved the first biosimilar application – an application by Sandoz to market a version of Amgen’s NEUPOGEN® (filgrastrim) biologic drug product.  Nevertheless, there is still a question as to when Sandoz will be able to begin selling its drug product, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

BIO Innovation Zone Company Snapshots: Protein Dynamic Solutions

BIO Innovation Zone

This month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Science Foundation (NSF) and the National Institutes of Health (NIH) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies. The SBIR/STTR program provides U.S. federal funding to small businesses engaged in research with the potential for commercialization. Each of the companies has been rigorously vetted through the SBIR/STTR review process Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Maximize Your Savings Potential During BIO International Convention

BIO-Business-Solutions-Tagline

$161,000,000 That’s how much BIO saved life science companies in aggregate on their 2014 purchases of products and services. More than 2,800 companies nationwide participate in the industry’s largest cost savings program known as BIO Business Solutions®, by taking advantage of the program’s preferential pricing and other benefits. Find out how your company can save money and become a partaker by stopping by the Member Services Pavilion at booth #2001 during the convention. BIO’s Member Services Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,